Latest Balance Sheet News

Vinyl Group Ltd reports a striking 190% revenue increase in FY25, driven by acquisitions and organic growth, while preparing for its first EBITDA positive quarter by December 2025.

Vinyl Group Ltd reported a striking 190% revenue increase for FY2025 but remains deep in the red with a $15.8 million loss. The company’s recent acquisitions and ongoing audit spotlight a pivotal moment for its future.

Nanollose Limited reported a $1.43 million loss for FY2025 while progressing pilot production of innovative biomaterials and strengthening its balance sheet with a $2.1 million capital raise. The company appointed a new CEO to drive commercialisation efforts in FY2026.

Bridge SaaS Limited reported a remarkable 524.6% revenue jump to $7.47 million for FY25, driven by its acquisition of Brightside Disability Support & Respite. Despite this growth, the company narrowed its loss to $1.13 million but remains unprofitable.

KneoMedia has narrowed its FY25 net loss by 38%, driven by cost controls and a strategic shift to its scalable KneoScience EdTech platform. The company also secured a $700,000 order for FY26, signaling growing traction in the US education market.

First Graphene Limited reported a 13% reduction in net loss for FY25 alongside steady revenue and expanding commercial demand for its PureGRAPH products.

Skin Elements Limited reported a 13% revenue increase and a 20% reduction in net loss for FY2025, as it progresses commercial roll-out of its natural biotech products including ECO-Nurture and SuprCuvr.

Rhythm Biosciences has significantly reduced its annual loss by 44%, boosted by a 91% rise in other income, while launching a new wholly owned subsidiary, RHY GeneType Pty Ltd.

Victor Group Holdings has sharply reduced its FY25 loss to $275,449 from $3.53 million the prior year, while expanding its fintech presence through strategic stakes in LIT Technology and iRich Finance.

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.

xReality Group (XRG) reports a landmark FY25 with 36% revenue growth driven by its Operator XR platform and a major US law enforcement contract. The company’s strategic shift towards immersive training technology signals robust momentum into FY26.

Cann Group Limited reported a significant 56% reduction in net loss for FY25, driven by cost cuts and strong growth in dried flower sales, even as revenue declined due to shifting product preferences. The company faces going concern challenges but is actively pursuing debt refinancing and operational improvements.